Una revisión centrada en el grupo 1 | 26 SEP 22

Hipertensión arterial pulmonar

Mecanismos, historia natural, genética y tratamiento de la hipertensión pulmonar arterial.
Autor/a: Paul M. Hassoun  N Engl J Med 2021;385:2361-76.
INDICE:  1. Texto principal | 2. Referencia bibliográfica
Referencia bibliográfica

1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53: 1801913.

2. von Romberg E. Über sklerose der lungenarterie. Dtsch Arch Klin Med 1891; 48:197-206.

3. Forssmann W. Die sondierung des rechten herzens. Klin Wochenschr 1929; 8:2085-7.

4. Richards DW. The contributions of right heart catheterization to physiology and medicine, with some observations on the physiopathology of pulmonary heart disease. Am Heart J 1957;54:161- 71.

5. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951;11:686-705.

6. Kay JM, Smith P, Heath D. Aminorex and the pulmonary circulation. Thorax 1971;26:262-70.

7. Hatano S, Strasser T, eds. Primary pulmonary hypertension: report on a WHO meeting, Geneva, 15–17 October, 1973. Geneva: World Health Organization, 1975.

8. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4.

9. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.

10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.

11. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013;168:871-80.

12. Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med 2018;6:577-9.

13. Wu W, He J, Shao X. Incidence and mortality trend of congenital heart disease at the global, regional, and national level, 1990–2017. Medicine (Baltimore) 2020;99(23):e20593.

14. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016;4:306-22.

15. Gorter TM, Hoendermis ES, van Veldhuisen DJ, et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 2016;18: 1472-87.

16. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013;1: 290-9.

17. Moore LG, Niermeyer S, Zamudio S. Human adaptation to high altitude: regional and life-cycle perspectives. Am J Phys Anthropol 1998;107:Suppl 27:25-64.

18. Deol AK, Fleming FM, Calvo-Urbano B, et al. Schistosomiasis — assessing progress toward the 2020 and 2025 global goals. N Engl J Med 2019;381:2519-28.

19. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV 2019;6(12):e831-e859.

20. Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res 2014;14:676.

21. Southgate L, Machado RD, Gräf S, Morrell NW. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol 2020;17:85- 95.

22. Wagenvoort CA. The pathology of primary pulmonary hypertension. J Pathol 1970;101:Pi.

23. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-21.

24. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev 2017;26:170056.

25. Gerges C, Gerges M, Friewald R, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: hemodynamic phenotyping and histomorphometric assessment. Circulation 2020;141: 376-86.

26. Fayyaz AU, Edwards WD, Maleszewski JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 2018;137:1796-810.

27. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65.

28. Galambos C, Sims-Lucas S, Abman SH, Cool CD. Intrapulmonary bronchopulmonary anastomoses and plexiform lesions in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2016;193:574-6.

29. Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185: 311-21.

30. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-7.

31. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:Suppl 1:S10-S19.

32. Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019;53:1801900.

33. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014;115:176-88.

34. Vanderpool RR, Pinsky MR, Naeije R, et al. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart 2015;101:37- 43.

35. Trip P, Kind T, van de Veerdonk MC, et al. Accurate assessment of load-independent right ventricular systolic function in patients with pulmonary hypertension. J Heart Lung Transplant 2013;32: 50-5.

36. Sanz J, Kariisa M, Dellegrottaglie S, et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging 2009;2:286-95.

37. Nie L, Li J, Zhang S, et al. Correlation between right ventricular-pulmonary artery coupling and the prognosis of patients with pulmonary arterial hypertension. Medicine (Baltimore) 2019;98(40): e17369.

38. Lahm T, Douglas IS, Archer SL, et al. Assessment of right ventricular function in the research setting: knowledge gaps and pathways forward. An official American Thoracic Society research statement. Am J Respir Crit Care Med 2018;198(4): e15-e43.

39. Kawut SM, Lima JAC, Barr RG, et al. Sex and race differences in right ventricular structure and function: the multiethnic study of atherosclerosis-right ventricle study. Circulation 2011;123:2542- 51.

40. Ventetuolo CE, Ouyang P, Bluemke DA, et al. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med 2011;183:659-67.

41. Jacobs W, van de Veerdonk MC, Trip P, et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest 2014; 145:1230-6.

42. Rain S, da Silva Goncalves Bos D, Handoko ML, et al. Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension. J Am Heart Assoc 2014;3(3):e000716.

43. Hsu S, Kokkonen-Simon KM, Kirk JA, et al. Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation 2018;137:2360-70.

44. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325- 34.

45. Harrison RE, Berger R, Haworth SG, et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005;111:435-41.

46. Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32:1385-9.

47. Gräf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun 2018;9:1416.

48. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012;5:336-43.

49. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013;369:351-61.

50. Kerstjens-Frederikse WS, Bongers EMHF, Roofthooft MTR, et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet 2013;50: 500-6.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023